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ore than 100 million musculoskeletal (tendon/muscle/bone) injuries
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cant proportion of these injures remain difficult to treat, and many individuals
have long-term pain and discomfort [2].
The International Olympic Committee (IOC) assembled an expert group to
discuss the nature of the problem, the current state of the art, and the need for
further research. Recent advances in this field relate to (1) the discovery of
novel genetic markers for risk of tendon injury; (2) improved understanding
of structure and composition of tendon and its response to loading; (3) increas-
ing clinical use of growth factors to treat a variety of tendon, bone and muscle
injuries; and (4) research exploring the potential of applying stem cells to ben-
efit patients who have musculoskeletal problems. This consensus statement
addresses each of these advances in more detail.
GENETIC PREDISPOSITION TO MUSCULOSKELETAL INJURY
Musculoskeletal injuries have complex causes including both genetic and non-
genetic factors [3]. The search for genes that may predispose athletes to these
injuries is gaining momentum but remains in its infancy. For example, variants
within two genes (which produce type V collagen and tenascin C, respectively)
were discovered recently to be associated with Achilles tendon pain [4,5]. Large
studies in various populations using high-throughput technologies such as
genomics and proteomics [6–8] will be required to advance knowledge of
genetic associations with musculoskeletal injuries. This approach will allow
researchers to identify further genes that may be associated with these and
other specific musculoskeletal injuries. The ability to identify people at risk
for these injuries will extend to the general population; injury-prevention mea-
sures will ensure that people can exercise appropriately for their inherited
genetic makeup.
STRUCTURE AND COMPOSITION OF TENDON
AND ITS RESPONSE TO LOADING
When athletes experience tendon pain, structural abnormalities are already
present [9,10]. At light microscopy, inflammatory cells generally are absent at
the site of injury [11]. Hence, the term ‘‘tendinitis’’ (or ‘‘tendonitis’’) has fallen
out of favor [12]. Injured tendon has several characteristic features, such as
increased or decreased cellularity and dramatic alteration in matrix structure
and composition [13]. There are quantitative and qualitative changes in colla-
gen, proteoglycan, and matrix-degrading enzymes and increased penetration
of blood vessels and nerves [14,15]. A classical term to describe this overall
appearance has been ‘‘tendinosis,’’ but these features are consistent with inad-
equate repair—a failed healing response [16].
Although load is important to maintain the normal tendon matrix, pathology
in tendons often is linked to overuse. Exercise can increase the production of
collagen and other proteins in tendons and thus can be used as part of the man-
agement of tendon injuries [17]. Tendon cells respond to load by increasing
protein production [17,18], but it is presently unclear what stimulus is required
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fully recover the normal matrix structure and composition, although adequate
pain-free function is still possible [9].INCREASING CLINICAL USE OF GROWTH FACTORS
Growth factors include a number of proteins secreted by cells [19]. Numerous
experimental studies have shown that growth factors are involved in bone and
cartilage formation, fracture healing, tendon and ligament repair, and skeletal
muscle regeneration [20–22]. Therefore their therapeutic use is of enormous
interest in the field of sports medicine and in helping treat workplace-related
injuries. Growth factors of current interest include growth hormone (GH),
insulin-like growth factor-1 (IGF-1), mechano growth factor (MGF), basic fibro-
blast growth factor (B-FGF), platelet-derived growth factor (PDGF), vascular
endothelial growth factor (VEGF), transforming growth factor–b (TGF-b),
and bone morphogenic protein (BMP) (Table 1). Several of these growth fac-
tors are available commercially and are used in clinical settings [23].
BMPs enhance healing during different stages of fracture healing in various
animal and human models. VEGF, PDGF, FGF, and TGF-b also have been
shown to play an important role in ligament and tendon healing [24–37].
Although a body of research evidence exists in animal models [38], the results
of late-stage, randomized, controlled clinical studies in humans are as yet un-
available (with the exception of BMPs), and the long-term local and systemic
effects of these agents are unknown [39]. FGFs, TGF-b, and PDGF are impor-
tant in the muscle regeneration process [22,40–47]. VEGF and PDGF increase
blood flow to skeletal muscle [48–50]. The administration of B-FGF to improve
blood perfusion has had limited success in other clinical studies, however
[51–54]. A phase II trial of B-FGF revealed positive effects on peripheral blood
flow [55].
Many fractures do not heal properly, and the bone-healing process therefore
needs to be augmented. Recombinant human bone morphogenetic proteinTable 1
Growth factor expression in musculoskeletal tissues
Factor Muscle Cartilage Tendon/ligament Bone
GH þ þ þ þ
IGF-1 þþ þ þ þ
MGF þþþ ? þ ?
B-FGF þ þ  þ
PDGF  –  
VEGF þ –  –
TGF-b  þ  þ
BMP þ þ – –
Abbreviations: B-FGF, basic fibroblast growth factor; BMP, bone morphogenic protein; GH, growth
hormone; IGF-1, insulin-like growth factor-1; MGF, mechano growth factor; PDGF, platelet-derived growth
factor; TGF-b, transforming growth factor–b; VEGF, vascular endothelial growth factor.
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1 have been used clinically. At present, there are several published clinical stud-
ies on the effects of BMPs in bone healing or in delayed unions/non-unions,
and several studies have reported the effects in fusion of the lumbar spine.
This use of BMPs now constitutes a well-established practice in orthopaedic
surgery.
GH, produced by the pituitary, induces the liver to produce systemic IGF-1,
which forms a tripartite binding complex with IGF binding protein 3 and the
acid labile subunit, to stabilize IGF-1 in the serum [56]. The levels of GH
and IGF-1 reach their peak during adolescence [57]. With increasing age, how-
ever, there is a marked decline in the circulating levels of GH and a somewhat
smaller decline in circulating IGF-1. Treatment of GH-deficient adults for an
extended period of time results in increased muscle strength and decreased
body fat [58]. These findings have encouraged the illicit use of GH and GH-
like substances among athletes, even those competing at the secondary school
level, in an attempt to enhance performance, an ongoing problem for anti-
doping agencies. At present, there aremethods for detectingGH and its isoforms,
but none have been validated for IGF-1 yet. Thematter is complicated by the fact
that local forms of IGF-1, such as MGF, are produced after exercise by the splic-
ing of the IGF-1 gene; its sequence differs from the regular endogenous type of
IGF-1 released by the liver but also is not detectable by current anti-doping
methods [59–64]. MGF is very potent for increasing muscle mass and strength
[65–67]. MGF apparently acts as a separate growth factor that is involved in ac-
tivating satellite cell proliferation and replenishing the pool of these muscle stem
cells [68,69]. In summary, studies in animal models have highlighted some inter-
esting candidates that await evaluation in human clinical trials.RESEARCH EXPLORING THE POTENTIAL OF APPLYING
STEM CELLS
Mesenchymal stem cells are adult tissue-producing cells that have been isolated
from various parts of the body, including cartilage, bone marrow, synovium,
adipose tissue, articular cartilage, muscle, and tendons [70–72]. Potentially,
mesenchymal stem cells can be used for tissue-engineering strategies through
implantation of scaffolds and gels, for gene delivery, and for production of
growth factor to stimulate tissue repair or inhibit tissue degradation [73–75].
Most studies have been conducted in animal models. Some studies of human
bone, cartilage, and tendons have produced positive results [76–78]. Further
controlled clinical trials in musculoskeletal injuries in humans are warranted,
however. Reasons for the lack of progress in this field include the need to
find the optimal sources of and methods for the differentiation of cells and
for the development of optimal surgical delivery materials and methods
[79,80]. Although some studies have shown negative effects, including ectopic
calcification and connective tissue overgrowth [78], further clinical trials should
be undertaken to determine whether long-term complications exist.
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FACTOR THERAPY
The implementation of new biologic therapies based on the administration of
growth factors and the manipulation of adult stem cells will require an
improved understanding of the genetic regulatory networks affected by these
agents. This understanding will be necessary for two reasons: to ensure that
these therapies are optimized and to ensure the safety of patients and athletes.
Knowledge of the genomic and proteomic impacts of growth factor–based ther-
apies on the target cells and of the biomarkers reflecting stem cell differentiation
status will underpin the development of tests capable of monitoring therapeutic
efficacy and minimizing adverse events.POTENTIAL FOR MISUSE OF GROWTH FACTORS
AND CELL-BASED THERAPIES
The ability to manipulate existing muscle cells and muscle stem cells has the
potential for use in the context of illegal performance enhancement. Knowledge
of the underlying genetic and cellular events affected by growth factor admin-
istration can be used to develop tests capable of detecting the illegal use of such
technologies for performance enhancement. The IOC will monitor develop-
ments in this field to ensure that such practices are discouraged, and detected
if used, by working with the anti-doping agencies.SCIENTIFIC ADVISORS
The IOC now has high-level scientific advisors who are capable of monitoring
new developments in the field of growth factor– and cell-based therapies and of
advising the IOC as to the use and abuse of these technologies. These advisors
will help ensure that athletes and coaches receive the benefits of these develop-
ments in improving their ability to prevent injury and to enhance therapy if
injured. In addition, the illegal use of these technologies for performance
enhancement will be increasingly difficult as methods of detecting such use
become available.References
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